IL1A and rheumatoid arthritis: IRAK4 targeting would have the advantage of inhibiting signaling by all IL-1 family cytokines as well as by almost all TLRs with a single drug, and, to that end, IRAK4 kinase inhibitors have been in development for RA, HS and lupus22–24.